Press coverage about FibroGen (NASDAQ:FGEN) has trended somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. FibroGen earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 43.6880098156399 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
- Quotidian Technical Highlights on Selected Biotech Stocks — Jun – KAIT Jonesboro, AR – Region 8 News, weather, sports (kait8.com)
- Quotidian Technical Highlights on Selected Biotech Stocks — Juno Therapeutics, Acorda Therapeutics, Lexicon Pharma, and FibroGen (medindia.net)
- Zacks: Brokerages Expect FibroGen Inc (FGEN) Will Post Quarterly Sales of $45.37 Million (americanbankingnews.com)
- FibroGen Inc (FGEN) CEO Sells $912,681.00 in Stock (americanbankingnews.com)
- Thomas B. Neff Sells 38,636 Shares of FibroGen Inc (FGEN) Stock (americanbankingnews.com)
Several brokerages have issued reports on FGEN. BidaskClub raised FibroGen from a “sell” rating to a “hold” rating in a research note on Thursday, December 21st. ValuEngine lowered FibroGen from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Mizuho reaffirmed a “hold” rating and issued a $61.00 target price on shares of FibroGen in a research note on Thursday, November 9th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $80.00 target price on shares of FibroGen in a research note on Thursday, September 14th. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $75.00 target price on shares of FibroGen in a research note on Tuesday, September 12th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $65.67.
In other FibroGen news, Director Kalevi Kurkijarvi sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 17th. The stock was sold at an average price of $52.24, for a total value of $104,480.00. Following the completion of the sale, the director now owns 26,000 shares in the company, valued at $1,358,240. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Thomas B. Neff sold 18,900 shares of the business’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $54.83, for a total value of $1,036,287.00. Following the completion of the sale, the chief executive officer now owns 3,176,861 shares of the company’s stock, valued at approximately $174,187,288.63. The disclosure for this sale can be found here. Insiders sold 291,346 shares of company stock valued at $14,395,148 in the last quarter. Corporate insiders own 13.60% of the company’s stock.
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.